Want to see HK:1177 full AI Analyst Report?
Top Page
Sino Biopharmaceutical
(1177)
Select Model
Select Model
Rating:63Neutral
Price Target:
HK$5.00
▼(-11.35% Downside)
Action:Reiterated
Date:08/21/26
The score is driven primarily by a solid financial base (strong gross profitability and improved free cash flow), but is tempered by weaker net profitability and higher leverage versus last year. Technicals are mixed with improving short-term trend but still below the 200-day average, and valuation is a key headwind due to the high P/E and modest dividend yield.
Positive Factors
Revenue Growth and Gross Margin
Revenue re-acceleration alongside consistently high gross margins indicates stronger demand and meaningful product economics. This combination can support reinvestment in research, regulatory development, and commercialization while giving the portfolio a durable base for growth over the next several quarters.
Negative Factors
Declining Net Profitability
The decline in net margin from about 12.1% to 7.4% shows that strong gross economics are not fully translating into bottom-line earnings. If this pressure persists, it can constrain reinvestment, weaken returns on equity, and make reported profit less dependable over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth and Gross Margin
Revenue re-acceleration alongside consistently high gross margins indicates stronger demand and meaningful product economics. This combination can support reinvestment in research, regulatory development, and commercialization while giving the portfolio a durable base for growth over the next several quarters.
Read all positive factors
Sino Biopharmaceutical (1177) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$85.83B
Dividend Yield2.49%
Average Volume (3M)62.76M
Price to Earnings (P/E)30.8
Beta (1Y)0.96
Revenue Growth14.57%
EPS Growth-31.09%
CountryHK
Employees22,838
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)0.13
Shares Outstanding18,682,953,000
10 Day Avg. Volume62,816,453
30 Day Avg. Volume62,756,329
Financial Highlights & Ratios
PEG Ratio1.42
Price to Book (P/B)3.27
Price to Sales (P/S)3.15
P/FCF Ratio13.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$8.93Price Target Upside58.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)0.26
Revenue Forecast (FY)HK$36.32B
Sino Biopharmaceutical Business Overview & Revenue Model
Company Description
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medi...
How the Company Makes Money
Sino Biopharmaceutical primarily makes money by selling pharmaceutical products it develops or licenses, with revenue recognized from the commercial sale and distribution of medicines. Its key revenue stream is product sales from its drug portfoli...
Sino Biopharmaceutical Financial Statement Overview
Summary
Income Statement
67
Positive
Balance Sheet
64
Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.70B | 31.83B | 28.87B | 26.20B | 26.03B | 26.86B |
| Gross Profit | 27.78B | 26.13B | 23.53B | 21.21B | 21.54B | 21.53B |
| EBITDA | 10.68B | 7.50B | 6.49B | 6.98B | 6.69B | 19.87B |
| Net Income | 2.39B | 2.34B | 3.50B | 2.33B | 2.54B | 14.61B |
Balance Sheet | ||||||
| Total Assets | 83.21B | 76.04B | 65.41B | 63.60B | 64.06B | 60.54B |
| Cash, Cash Equivalents and Short-Term Investments | 27.58B | 22.96B | 14.60B | 14.12B | 16.92B | 15.79B |
| Total Debt | 17.17B | 16.08B | 9.78B | 12.58B | 13.98B | 12.12B |
| Total Liabilities | 36.96B | 33.92B | 22.63B | 25.43B | 26.12B | 22.81B |
| Stockholders Equity | 32.57B | 30.68B | 31.96B | 30.47B | 29.75B | 30.29B |
Cash Flow | ||||||
| Free Cash Flow | 5.16B | 7.59B | 5.22B | 4.36B | 4.56B | 3.47B |
| Operating Cash Flow | 6.13B | 9.29B | 6.62B | 6.07B | 6.27B | 5.37B |
| Investing Cash Flow | -5.13B | -12.41B | -1.71B | -756.98M | -4.07B | -2.52B |
| Financing Cash Flow | 2.58B | 4.16B | -6.32B | -6.55B | -3.19B | -3.23B |
Sino Biopharmaceutical Technical Analysis
Negative
5.64
Price Trends
5.42
Negative
5.10
Negative
5.46
Negative
Market Momentum
-0.17
Positive
35.57
Neutral
15.58
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1177, the sentiment is Negative. The current price of 5.64 is above the 20-day moving average (MA) of 5.24, above the 50-day MA of 5.42, and above the 200-day MA of 5.46, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 35.57 is Neutral, neither overbought nor oversold. The STOCH value of 15.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1177.
Sino Biopharmaceutical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | HK$34.37B | 3.46 | 30.16% | 1.85% | 101.73% | 249.15% | |
63 Neutral | HK$85.83B | 30.75 | 7.56% | 2.49% | 14.57% | -31.09% | |
63 Neutral | HK$139.32B | 95.59 | 6.06% | ― | 42.64% | 9.67% | |
60 Neutral | HK$26.75B | 26.18 | 20.41% | ― | 32.63% | 8.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$76.70B | -66.50 | -10.86% | ― | 42.47% | -15.80% | |
41 Neutral | HK$30.07B | -69.15 | -7.23% | ― | 35.82% | 54.40% |
* Healthcare Sector Average
HK:1177
Sino Biopharmaceutical
4.82
-2.13
-30.64%
HK:1801
Innovent Biologics
79.75
-10.45
-11.59%
HK:1530
3SBio
13.54
-17.78
-56.76%
HK:9926
Akeso, Inc.
81.50
-36.80
-31.11%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
15.26
-11.44
-42.85%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
49.06
-20.04
-29.00%
Sino Biopharmaceutical Corporate Events
Sino Biopharm Wins Breakthrough Status for Two Hepatitis B Drugs in China
Oct 27, 2026
Sino Biopharmaceutical has announced that two hepatitis B drug candidates developed by its subsidiary Chia Tai Tianqing, the TLR7 agonist TQ-A3334 and core protein allosteric modulator TQA3605, have been granted Breakthrough Therapy Designation by...
Sino Biopharm’s HER2 ADC TQB2102 Shows Strong Phase 3 Results in HER2-Low Breast Cancer
Oct 26, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has reported new data from two clinical studies of its next-generation HER2 biparatopic antibody-drug conjugate TQB2102, developed to simultaneously target ECD2 and ECD4 domains of HER2 a...
Sino Biopharm Advances First Homegrown TSLP Antibody Into Late-Stage Trials
Oct 21, 2026
Sino Biopharmaceutical announced that all participants have been enrolled in a Phase III registrational clinical trial for TQC2731, a humanised TSLP monoclonal antibody developed by subsidiary Chai Tai Tianqing for maintenance treatment of chronic...
Sino Biopharm Showcases Key Hepatitis B Drug Data at 2026 AASLD Meeting
Oct 14, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has advanced its liver disease portfolio, with its independently developed oral TLR7 agonist TQ-A3334 selected as a Late-Breaking Abstract for oral presentation at the 2026 Liver Meeting ...
Sino Biopharm Completes Phase III Enrollment for Novel COPD Inhalation Drug
Oct 8, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has completed patient enrollment in a Phase III pivotal registrational trial of TQC3721 inhalation suspension, a dual PDE3/4 inhibitor for maintenance treatment of chronic obstructive pul...
Sino Biopharm Strikes STADA Biosimilars Deal to Expand Global Oncology Reach
Sep 28, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has entered a strategic biosimilars partnership with Germany’s STADA, granting STADA exclusive rights to commercialize a pembrolizumab biosimilar across the EU, Switzerland, the U.K...
Sino Biopharm’s IL-4R Antibody for Atopic Dermatitis Clears Key Regulatory Hurdle in China
Sep 15, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has secured acceptance of a new drug application in China for TQH2722, a fully human IL-4Rα monoclonal antibody injection for adults with moderate-to-severe atopic dermatitis inadequ...
Sino Biopharmaceutical’s HER2-Low Breast Cancer ADC Wins China NDA Acceptance
Sep 15, 2026
Sino Biopharmaceutical announced that China’s Center for Drug Evaluation has accepted a new drug application for TQB2102, a HER2 dual-epitope bispecific antibody-drug conjugate for adult patients with unresectable or metastatic HER2-low brea...
Sino Biopharm Raises CT Tianqing Stake to 65% in RMB4.48 Billion Deal
Sep 11, 2026
Sino Biopharmaceutical is a Hong Kong-listed pharmaceutical group focused on innovative and generic medicines, with a strong presence in the Chinese market. Its subsidiary CT Tianqing is a key growth engine, developing novel therapies and expandin...
Sino Biopharm Showcases Promising Oral STAT6 Degrader Data at ERS 2026
Sep 8, 2026
Sino Biopharmaceutical announced that its subsidiary Chia Tai Tianqing has presented preclinical data on TQH5528, an oral STAT6 degrader, at the European Respiratory Society 2026 Annual Congress. The candidate is built on the company’s propr...
Sino Biopharm’s TQC3721 COPD Inhaler Shows Strong Phase I Data
Sep 7, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has advanced its novel dual PDE3/4 inhibitor TQC3721 for COPD, developing both nebulised suspension and dry powder inhaler formulations that combine bronchodilation and anti‑inflamm...
Sino Biopharm Wins FDA Green Light for Novel GPC3-Targeting Cancer ADC Trial
Sep 3, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has secured U.S. FDA investigational new drug approval to begin clinical trials of TQB6426, a self-developed GPC3-targeting antibody-drug conjugate for advanced malignant tumors, notably ...
Sino Biopharm Strikes Exclusive HER2 ADC Deal With Cipla to Boost Emerging-Market Reach
Aug 31, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has signed an exclusive license and supply agreement with Cipla for TQB2102, a next-generation HER2 bispecific antibody-drug conjugate, covering India, South Africa and five other emergin...
Sino Biopharm’s Kylo-11 Shows Year-Long Lp(a) Cut in Phase I Trial
Aug 31, 2026
Sino Biopharmaceutical reported final Phase I data for Kylo-11, a long-acting siRNA drug targeting the LPA gene, showing profound and durable reductions in lipoprotein(a) after a single subcutaneous dose. Results presented at the European Society ...
Sino Biopharm Wins China, U.S. Green Lights for Next-Gen Nectin-4 ADC LM-364
Aug 28, 2026
Sino Biopharmaceutical’s subsidiary LaNova Medicines has secured clinical trial approval in China for LM-364, a next-generation Nectin-4 tumor microenvironment-responsive antibody-drug conjugate for advanced solid tumors, following earlier c...
Sino Biopharm Wins Trial Nod for Novel Obesity Antibody TQF6422
Aug 21, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has obtained approval from China’s drug regulator to begin clinical trials of TQF6422, a fully human ActRII A/B monoclonal antibody for weight management in obese and overweight adu...
Sino Biopharmaceutical Interim Results Highlight Surge in Innovative Drug and Out-Licensing Revenue
Aug 19, 2026
Sino Biopharmaceutical reported solid interim results for the six months ended 30 June 2026, with revenue rising 10.6% year-on-year to RMB19.44 billion and profit attributable to shareholders edging up 1.4% to RMB3.43 billion. The company declared...
Sino Biopharmaceutical Declares 2026 Interim Dividend of HKD 0.07 Per Share
Aug 19, 2026
Sino Biopharmaceutical Limited has announced an interim ordinary cash dividend of HKD 0.07 per share for the six months ended 30 June 2026, payable in Hong Kong dollars. The ex-dividend date is set for 1 September 2026, with the record date on 4 S...
Sino Biopharm Wins NMPA Approval for New First-Line Lung Cancer Regimen
Aug 7, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has secured approval from China’s National Medical Products Administration for a new first-line regimen for locally advanced or metastatic squamous non-small cell lung cancer. The t...
Sino Biopharm Wins Approval for Next-Generation Flurbiprofen Pain Patch
Aug 6, 2026
Sino Biopharmaceutical’s subsidiary Beijing Tide Pharmaceutical has secured approval from China’s National Medical Products Administration to market a second-generation flurbiprofen patch for a broad range of pain and inflammatory indi...
Sino Biopharmaceutical Sets Board Meeting to Approve Interim Results and Consider Dividend
Aug 6, 2026
Sino Biopharmaceutical Limited has scheduled a board meeting for 19 August 2026 to approve the publication of its unaudited interim results for the six months ended 30 June 2026 and to consider the declaration of an interim dividend. The outcome o...
Sino Biopharm Wins China CDE Acceptance for Novel Leukemia Drug TQB3909
Aug 4, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has had its new drug application for TQB3909, a Category 1 innovative BCL-2 inhibitor tablet, accepted by China’s Center for Drug Evaluation for use in adult patients with relapsed ...
Sino Biopharm’s HER2 bispecific ADC TQB2102 gains third breakthrough tag in China
Aug 3, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has secured a third Breakthrough Therapy Designation in China for its next-generation HER2 bispecific antibody-drug conjugate TQB2102, this time for adult patients with unresectable or me...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.